Deepexi Technology Co., Ltd.
滴普科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1384)

PROPOSED APPOINTMENT OF AN INDEPENDENT NON-EXECUTIVE DIRECTOR AND RESIGNATION OF AN INDEPENDENT NON-EXECUTIVE DIRECTOR

This announcement is made by Deepexi Technology Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Hong Kong Stock Exchange**") (the "**Listing Rules**").

PROPOSED APPOINTMENT OF AN INDEPENDENT NON-EXECUTIVE DIRECTOR

The board of directors of the Company (the "**Board**") hereby announces that, after taking into consideration the recommendation from the nomination committee of the Board, the Board has considered and approved the proposed appointment of Mr. Fung Che Wai, Anthony (馮志偉) ("**Mr. Fung**") as an independent non-executive Director of the Company. The proposed appointment of Mr. Fung shall be subject to the approval by the shareholders by an ordinary resolution at the EGM, and will take effect on the date of approval at the EGM.

Biographical details of Mr. Fung are set out below:

Mr. Fung Che Wai, Anthony, aged 57. Mr. Fung has over 33 years of experience in accounting, consultancy services, investor relations and financial management. From August 1992 to September 1999, Mr. Fung was an auditor at Deloitte Touche Tohmatsu, an accounting firm where he was primarily responsible for providing audit services. From October 1999 to August 2007, Mr. Fung was a director of Winsmart Consultants Limited (弘陞投資顧問有限公司), a financial consulting company where he was primarily responsible for advising on pre-listing matters. From January 2008 to August 2010, he was the vice president of NagaCorp Ltd. (金界控股有限公司), a company listed on the Hong Kong Stock Exchange (stock code: 3918), where he was primarily responsible for investor relations matters. From January 2011 to July 2014, Mr. Fung was the chief financial officer and company secretary of Zall Smart Commerce Group Ltd. (卓爾智聯集團有限公司), a company listed on the Hong Kong Stock Exchange (stock code: 2098), where he was primarily responsible for financial management. From July 2014 to April 2017, Mr. Fung was the chief financial officer and company secretary of Kong Sun Holdings Limited (江山控股有限公司), a company listed on the Hong Kong Stock Exchange (stock code: 295), where he was primarily responsible for financial management. From May 2017 to December 2022, he was the chief financial officer and company secretary of Beijing Enterprises Urban Resources Group Limited (北控城市資源集團有限公司), a company listed on the Hong Kong Stock Exchange (stock code: 3718), where he was primarily responsible for financial management. Mr. Fung also served as an independent non-executive director of FY Financial (Shenzhen) Co., Ltd. (富銀融資租賃(深圳)股份有限公司), a company listed on the Hong Kong Stock Exchange (stock code: 8452), from April 2017 to August 2023; an independent non-executive director of S&P International Holding Limited (椰豐集團有限公司), a company listed on the Hong Kong Stock Exchange (stock code: 1695), from June 2017 to October 2021; and an independent non-executive director of Dekon Food and Agriculture Group (四川德康農牧食品集團股份有限公司), a company listed on the Hong Kong Stock Exchange (stock code: 2419), from October 2023 to February 2026, primarily responsible for providing independent advice to the boards of directors of the aforementioned companies.

In addition, Mr. Fung has been an independent non-executive director of KWG Living Group Holdings Limited (合景悠活集團控股有限公司), a company listed on the Hong Kong Stock Exchange (stock code: 3913), Zhong An Group Limited (眾安集團有限公司), a company listed on the Hong Kong Stock Exchange (stock code: 672), Zhejiang Taimei Medical Technology Co., Ltd. (浙江太美醫療科技股份有限公司), a company listed on the Hong Kong Stock Exchange (stock code: 2576), XXF Group Holdings Limited (喜相逢集團控股有限公司), a company listed on the Hong Kong Stock Exchange (stock code: 2473) and Qyuns Therapeutics Co., Ltd. (江蘇荃信生物醫藥股份有限公司), a company listed on the Hong Kong Stock Exchange (stock code: 2509) since October 2020, November 2021, September 2023, October 2023 and January 2024, respectively, and is primarily responsible for providing independent advice to the boards of directors of the aforementioned companies.

Mr. Fung obtained his bachelor's degree in accounting from The Hong Kong Polytechnic University (formerly known as Hong Kong Polytechnic) in October 1992. He was admitted as a fellow member of the Association of Chartered Certified Accountants (ACCA) in October 2001, and as a fellow member of the Hong Kong Institute of Certified Public Accountants in September 2005.

Subject to the approval of appointment of Mr. Fung as an independent non-executive Director by the shareholders at the EGM, the Company will enter into a letter of appointment with Mr. Fung. The term of office of Mr. Fung will commence from the date of approval of his appointment at the EGM and end upon the expiration of the term of the first session of the Board, and he may be re-elected upon the expiration of his term.

The Director's remuneration of Mr. Fung is proposed to be HK$300,000 per annum, which is determined by the Board based on the recommendation from the remuneration and appraisal committee of the Board, with reference to his duties and responsibilities as well as prevailing market conditions, and will be reviewed by the remuneration and appraisal committee of the Board from time to time.

Mr. Fung has confirmed that (i) he meets each of the independence factors as set out in Rule 3.13(1) to (8) of the Listing Rules; (ii) he has no past or present financial or other interests in the business of the Company or its subsidiaries or any connection with any core connected person (as defined in the Listing Rules) of the Company; and (iii) there are no other factors that may affect his independence as of the date of this announcement. The Board also considers that Mr. Fung has the character, integrity, independence and professional experience required for an independent non-executive Director, and that he is able to devote sufficient time to discharging his duties as an independent non-executive Director of the Company.

In recommending the appointment of Mr. Fung as an independent non-executive Director, the nomination committee has taken into account a variety of factors in accordance with the Board diversity policy adopted by the Company, including but not limited to gender, age, cultural and educational background, professional experience, skills, knowledge and length of service, aiming to achieve diversity of the Board. In assessing Mr. Fung's proposed time and contributions devoted to the Board, as well as his ability to effectively perform his duties, the nomination committee has given particular consideration to the time he devoted to other significant external engagements (including his other current directorships and time commitments), as well as factors or circumstances relating to his character, integrity, independence and experience. The nomination committee is of the view that Mr. Fung has extensive experience in accounting, consultancy services, investor relations and financial management, and that his appointment will bring valuable expertise, independent opinions, and diverse perspectives to the Board, as well as contribute to enhancing the Company's governance standards. Accordingly, the nomination committee recommended the proposed appointment of Mr. Fung as an independent non-executive Director to the Board after consideration.

Save as disclosed above, as at the date of this announcement, Mr. Fung (i) does not hold any positions with the Company or other members of the Group; (ii) did not hold any directorships in public companies listed on any securities market in Hong Kong or overseas in the last three years; (iii) does not have any relationships with any Directors, supervisors, senior management, substantial shareholders or controlling shareholders of the Company; and (iv) does not have any interest or short positions in any shares, underlying shares or debentures of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, there is no other information relating to the proposed appointment of Mr. Fung that shall be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules nor any other matters which need to be brought to the attention of the shareholders.

A circular containing, among others, further details of the proposed appointment of Mr. Fung as an independent non-executive Director, together with the notice of the EGM, will be published on the websites of the Company and the Stock Exchange in due course.

RESIGNATION OF AN INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board also announces that, due to the need to devote more time and attention to his other personal and business affairs, Mr. Zhang Jielong ("**Mr. Zhang**") intends to resign as an independent non-executive Director of the Company, the chairman of the audit committee of the Board, and a member of the nomination committee of the Board. Such resignation will take effect from the date on which Mr. Fung is appointed as an independent non-executive Director.

Mr. Zhang has confirmed that he has no disagreement with the Board and there is no matter relating to his proposed resignation that needs to be brought to the attention of the shareholders and the Stock Exchange.

The Board would like to express its sincere gratitude to Mr. Zhang for his valuable contributions to the Company during his tenure of office.

By Order of the Board
Deepexi Technology Co., Ltd.
Mr. Zhao Jiehui
Chairman of the Board, Executive Director and Chief Executive Officer

Beijing, the PRC
July 20, 2026

As at the date of this announcement, the Board of the Company comprises: (i) Mr. Zhao Jiehui, Mr. Yang Lei, Dr. Li Qiang, Mr. Cao Lianfei and Ms. Shi Yi as executive Directors; (ii) Mr. Wang Zhenghao as a non-executive Director; and (iii) Dr. Feng Wei, Dr. Kong Xianguang and Mr. Zhang Jielong as independent non-executive Directors.